According to Technavio’s latest market research study, the global gastroparesis drugs market is expected to grow at a CAGR of more than 3% during the forecast period, 2017-2021.
This report by Technavio provides an in-depth analysis of the global gastroparesis drugs market in terms of revenue and emerging market trends. The report also includes an up-to-date analysis and forecasts for various market segments and all geographical regions.
Technavio research analysts categorize the market based on the disease type
Click here to request a free sample of this report
The top three revenue contributing disease segments are discussed below
Global idiopathic gastroparesis market: Development of new and effective therapies is needed for the symptomatic control of idiopathic gastroparesis. For instance, people living in the US at present do not have any FDA-approved drug for the treatment of idiopathic gastroparesis. Such instances indicate the potential to address unmet needs of the market, which in turn, will drive the idiopathic gastroparesis market.
“Idiopathic gastroparesis is the most common form of gastroparesis and holds the largest share in the global gastroparesis market. Idiopathic gastroparesis is more commonly seen in women, especially in young or middle-aged women,” says Barath Palada, a lead analyst at Technavio for research on cardiovascular and metabolic disorders.
Global diabetic gastroparesis drugs market: Diabetic gastroparesis is expected to be the fastest growing market during the forecasted period. The adverse effect of high post meal blood sugars on vagus nerves is the major factors causing gastroparesis. Technavio’s market research analysts estimate the global diabetic gastroparesis drugs market to register growth at a CAGR of more than 4% between 2017 and 2021. The rising number of diabetes patients globally is expected to be the major factor driving the global diabetic gastroparesis market. For instance, in 2015, around 400-425 million people had diabetes globally, the number is expected to rise to around 625-650 million by 2040.
Global gastroparesis drugs market by others: There are several other causes of gastroparesis, post-gastric surgery being the most common of them. The growth of this market is driven primarily by the rising number of gastric surgeries. Parkinson’s disease is another cause of gastroparesis and the incidence of this disease has been rising over the last few years. This rise in demand for other gastroparesis drugs is expected to continue during the forecast period due to the rising cases of Parkinson’s disease across the globe.
The top vendors operating in the global gastroparesis drugs market are:
- Cadila Pharmaceuticals
- GlaxoSmithKline
- Johnson & Johnson
- Valeant
Other prominent vendors in the market include Evoke Pharma, Teva Pharmaceutical Industries, and Theravance Biopharma.
A more detailed analysis is available in the Technavio report titled, ‘Global Gastroparesis Drugs Market 2017-2021’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports
- Global Botanical and Plant-Derived Drugs Market 2017-2021
- Global Therapeutic Drug Monitoring Market 2017-2021
- Global Intravenous Iron Drugs Market 2017-2021
To read more press releases – click here
